Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study
The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based o...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2019-10-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3331
|
| _version_ | 1818321543656112128 |
|---|---|
| author | Nikolai Dyrberg Loft Alexander Egeberg Mads Kirchheiner Rasmussen Lars Erik Bryld Robert Gniadecki Tomas Norman Dam Lars Iversen Lone Skov |
| author_facet | Nikolai Dyrberg Loft Alexander Egeberg Mads Kirchheiner Rasmussen Lars Erik Bryld Robert Gniadecki Tomas Norman Dam Lars Iversen Lone Skov |
| author_sort | Nikolai Dyrberg Loft |
| collection | DOAJ |
| description | The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based on data from the Danish national registry (DERMBIO), this study investigated the correlation between changes in PASI and DLQI in a cohort of patients with moderate-to-severe psoriasis treated with biologics or apremilast using Spearman’s rank correlation analyses. The correlation analysis of 1,677 patients, of whom 276 had available data after 5 years, showed weak-to-moderate correlation between PASI and DLQI during a 5-year period and between changes in PASI and DLQI: 0.58 (p < 0.0001) for baseline to 3 months and 0.42 (p < 0.0001) for 3 to 12 months. The first question on “Symptoms and feelings” made up the largest proportion of the overall DLQI. The correlation between PASI and DLQI is weak-to-moderate and varies over time. Changes in PASI correlate weak-to-moderately with changes in DLQI during the first 12 months of treatment, with symptoms being the most important factor contributing to impaired quality of life. |
| first_indexed | 2024-12-13T10:42:35Z |
| format | Article |
| id | doaj.art-43d9114180374464a9a81b25b406270b |
| institution | Directory Open Access Journal |
| issn | 0001-5555 1651-2057 |
| language | English |
| last_indexed | 2024-12-13T10:42:35Z |
| publishDate | 2019-10-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj.art-43d9114180374464a9a81b25b406270b2022-12-21T23:50:26ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572019-10-0199131224123010.2340/00015555-33315597Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide StudyNikolai Dyrberg Loft0Alexander EgebergMads Kirchheiner RasmussenLars Erik BryldRobert GniadeckiTomas Norman DamLars IversenLone Skov Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark. nikolai.dyrberg.loft@regionh.dk. The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based on data from the Danish national registry (DERMBIO), this study investigated the correlation between changes in PASI and DLQI in a cohort of patients with moderate-to-severe psoriasis treated with biologics or apremilast using Spearman’s rank correlation analyses. The correlation analysis of 1,677 patients, of whom 276 had available data after 5 years, showed weak-to-moderate correlation between PASI and DLQI during a 5-year period and between changes in PASI and DLQI: 0.58 (p < 0.0001) for baseline to 3 months and 0.42 (p < 0.0001) for 3 to 12 months. The first question on “Symptoms and feelings” made up the largest proportion of the overall DLQI. The correlation between PASI and DLQI is weak-to-moderate and varies over time. Changes in PASI correlate weak-to-moderately with changes in DLQI during the first 12 months of treatment, with symptoms being the most important factor contributing to impaired quality of life. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3331 psoriasis patient-reported outcomes psoriasis area and severity index dermatology life quality index biologics |
| spellingShingle | Nikolai Dyrberg Loft Alexander Egeberg Mads Kirchheiner Rasmussen Lars Erik Bryld Robert Gniadecki Tomas Norman Dam Lars Iversen Lone Skov Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study Acta Dermato-Venereologica psoriasis patient-reported outcomes psoriasis area and severity index dermatology life quality index biologics |
| title | Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study |
| title_full | Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study |
| title_fullStr | Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study |
| title_full_unstemmed | Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study |
| title_short | Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study |
| title_sort | patient reported outcomes during treatment in patients with moderate to severe psoriasis a danish nationwide study |
| topic | psoriasis patient-reported outcomes psoriasis area and severity index dermatology life quality index biologics |
| url |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3331
|
| work_keys_str_mv | AT nikolaidyrbergloft patientreportedoutcomesduringtreatmentinpatientswithmoderatetoseverepsoriasisadanishnationwidestudy AT alexanderegeberg patientreportedoutcomesduringtreatmentinpatientswithmoderatetoseverepsoriasisadanishnationwidestudy AT madskirchheinerrasmussen patientreportedoutcomesduringtreatmentinpatientswithmoderatetoseverepsoriasisadanishnationwidestudy AT larserikbryld patientreportedoutcomesduringtreatmentinpatientswithmoderatetoseverepsoriasisadanishnationwidestudy AT robertgniadecki patientreportedoutcomesduringtreatmentinpatientswithmoderatetoseverepsoriasisadanishnationwidestudy AT tomasnormandam patientreportedoutcomesduringtreatmentinpatientswithmoderatetoseverepsoriasisadanishnationwidestudy AT larsiversen patientreportedoutcomesduringtreatmentinpatientswithmoderatetoseverepsoriasisadanishnationwidestudy AT loneskov patientreportedoutcomesduringtreatmentinpatientswithmoderatetoseverepsoriasisadanishnationwidestudy |